Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EEF2K | O00418 | 1/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.32 |
| ▸ | PGR | P06401 | 2/20 | 0.32 |
| ▸ | TOP2A | P11388 | 1/20 | 0.32 |
| ▸ | TOP2B | Q02880 | 1/20 | 0.32 |
| ▸ | JAK2 | O60674 | 2/20 | 0.31 |
| ▸ | JAK1 | P23458 | 2/20 | 0.31 |
| ▸ | TYK2 | P29597 | 2/20 | 0.31 |
| ▸ | JAK3 | P52333 | 2/20 | 0.31 |
| ▸ | DRD1 | P21728 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.30 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4515223 | 0.85 | ALDH1A1 (0.38) | EEF2KOPRM1TOP2ATOP2BALDH1A1 | |
| SCHEMBL6648240 | 0.84 | EEF2K (0.36) | EEF2KOPRM1PGRJAK2JAK1 | |
| SCHEMBL6669096 | 0.83 | JAK2 (0.35) | EEF2KOPRM1PGRTOP2ATOP2B | |
| SCHEMBL6673449 | 0.82 | KCNH2 (0.46) | CYP2C9CYP2C19 | |
| SCHEMBL6647130 | 0.81 | EEF2K (0.37) | EEF2KOPRM1PGRTOP2ATOP2B | |
| SCHEMBL12835813 | 0.79 | JAK2 (0.33) | EEF2KJAK2JAK1TYK2JAK3 | |
| SCHEMBL12835810 | 0.78 | EEF2K (0.41) | EEF2KPGRTOP2ATOP2BJAK2 | |
| SCHEMBL4505813 | 0.78 | TOP2A (0.39) | EEF2KOPRM1PGRTOP2ATOP2B | |
| SCHEMBL6670965 | 0.78 | JAK2 (0.33) | EEF2KOPRM1JAK2JAK1TYK2 | |
| SCHEMBL6377126 | 0.77 | KCNH2 (0.34) | EEF2KCYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1401830-A2 | QUINAZOLINEDIONES AS ANTIBACTERIAL AGENTS | Warner-Lambert Company LLC (US) | 2004-03-31 | — | — | EP | disclosed |
| US-20030114666-A1 | Having quinazolindione core structure; non-antibiotic resistance | WARNER-LAMBERT COMPANY | 2003-06-19 | — | — | US | disclosed |
| WO-2002102793-A2 | QUINAZOLINEDIONES AS ANTIBACTERIAL AGENTS | WARNER-LAMBERT COMPANY LLC (US) | 2002-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030114666-A1 | Having quinazolindione core structure; non-antibiotic resistance | ABCC1, RPS6KA1, SIGMAR1 | EEF2K 700/4885OPRM1 906/4885PGR 4064/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.